IKE Tech Submits PMTA and TPMF Applications for Blockchain-Based Age Verification Component to FDA

May.06.2025
IKE Tech Submits PMTA and TPMF Applications for Blockchain-Based Age Verification Component to FDA
IKE Tech LLC announced that it has submitted a Premarket Tobacco Application (PMTA) and a Tobacco Product Master File (TPMF) to the U.S. Food and Drug Administration (FDA). The submitted products include a blockchain-based Bluetooth Low Energy (BLE) system-on-chip and a smartphone identity and age verification application.

Key points:

 

1.IKE Tech LLC announced on May 1st that they have submitted their blockchain-based Bluetooth Low Energy (BLE) system chip and smartphone identity and age verification application PMTA and TPMF to the United States FDA.

 

2.For the first time, the company has submitted a full PMTA application for an independent, scalable age verification component, which can provide real-time, continuous age verification at points of use in electronic nicotine delivery systems (ENDS).

 

3.Company background: IKE Tech LLC is a joint venture composed of Ispire Technology Inc., Touch Point Worldwide Inc. (operating under the name Berify), and Chemular Inc., committed to innovating identity and age verification (IAV) technology solutions.


IKE Tech LLC announced on May 1 that it has submitted a premarket tobacco product application (PMTA) and a tobacco product master file (TPMF) to the US Food and Drug Administration (FDA) for its blockchain-based Bluetooth Low Energy (BLE) system chip and smartphone identity and age verification application components.

 

The company stated, "This is the first time a complete PMTA application has been submitted for an independent, scalable age verification component that can provide real-time, continuous age verification at the point of use for electronic nicotine delivery systems (ENDS). The IKE system is designed to achieve universal integration with all ENDS devices, utilizing a unique blockchain-based tokenization technology to further ensure user privacy and security.

 

IKE Tech stated in a multi-center human factor validation study submitted to the PMTA that their system has demonstrated 100% effectiveness in preventing individuals under 21 from activating the device. The company has formally requested an expedited review of their application, emphasizing the potential of the system in enhancing public health.

 

Ispire CEO Michael Wang stated, "Ispire will not only benefit from the commercial sales of this component, but also from the rights to integrate this technology into our own devices - allowing us to lead in compliant innovation and unlock new revenue opportunities.

 

John Patterson, President of IKE Tech, stated, "This is a significant milestone for IKE Tech and the ENDS category. We are not just building technology, we are laying the groundwork for a new regulatory framework to provide FDA and manufacturers with powerful tools to protect public health and ensure that only adults use e-cigarette products. By integrating validated and scalable age verification technology into ENDS devices, the industry now has a real opportunity to completely eliminate the issue of underage e-cigarette use.

 

Unlike existing solutions that allow permanent access after disposable verification at the time of purchase, IKE's system requires continuous verification to maintain device access. Human verification research shows that 91% of users (aged between 18 and 67) find the app to be "very easy" or "extremely easy" to use, with a user error rate of less than 0.8%.

 

IKE Tech LLC is a joint venture formed by three technology and research companies - Ispire Technology Inc., Touch Point Worldwide Inc. (operating under the name Berify), and Chemular Inc. - dedicated to innovating identity and age verification (IAV) technology solutions.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Extends Vape Rules to Unmanned Stores After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's Ministry of Gender Equality and Family said on September 14 that it plans to designate unmanned e-cigarette stores as businesses where minors are prohibited from entering or working. Operators would be required to verify customers' ages and display notices restricting access by minors. The proposal is open for public comment through October 6. The move follows an April expansion of South Korea's statutory tobacco definition that brought products made with natural or synthetic nicotine under the Tobacco Business Act. Nicotine-free liquids and products using nicotine analogues such as 6-methylnicotine, however, remain an emerging regulatory issue.
Sep.21
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Philip Morris Korea launched TEREA ONYX, a new tobacco stick line for IQOS ILUMA devices, on October 15, 2026. The initial products, AMANG PEARL and CALI PEARL, feature tropical-inspired flavors, Fresh Filters and capsules designed to deliver different flavor experiences before and after activation. Both are priced at KRW 4,800 per pack and are available at convenience stores nationwide and IQOS-operated stores in South Korea. The launch expands the Korean TEREA portfolio from four product lines to five, following earlier capsule tobacco stick additions in 2026.
product
Oct.23
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11